Anti-HSV-2 refers to antibodies (commonly measured as IgG and sometimes IgM) that target proteins on herpes simplex virus type 2, an alpha-herpesvirus. Serologic testing for HSV-2 antibodies has been used for decades in epidemiology and clinical research to document prior exposure and immune response patterns. Biologically, these antibodies are products of the adaptive humoral immune system. They arise when B cells recognize viral antigens, mature into plasma cells, and produce specific immunoglobulins that can bind viral components, contribute to opsonization, and form immunologic memory. In a neuroimmune context, antibody presence or changes in titer can reflect past exposure, immune boosting, or reactivation events that may influence systemic or neural immune signaling.

Elevated Anti-HSV-2 levels often indicate past exposure with a measurable antibody response and can reflect recent immune boosting or reactivation that increases circulating antibody titers. Higher levels may be associated with greater infection-related immune signaling, but they do not by themselves confirm current viral replication. Low or undetectable Anti-HSV-2 levels may indicate no prior exposure, testing during the early window before seroconversion, waning antibodies over long time, or reduced antibody production in the setting of weakened humoral immunity. Interpretation is most meaningful when considered alongside other Neural Zoomer markers, clinical history, and timing of sample collection.

Anti-HSV-2 is included in the Neural Zoomer’s infection-associated markers to identify prior exposure or immune activation related to herpes simplex virus type 2. Its measurement helps clinicians contextualize infection-linked immune signals alongside markers of neuroinflammation, barrier integrity, and autoimmunity, supporting a more integrated, personalized view of factors that may relate to neurological symptoms.